Medpace Holdings Inc ((MEDP)), Edgewise Therapeutics, Inc. ((EWTX)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Medpace Holdings Inc. and Edgewise Therapeutics, Inc. have announced an update on their ongoing clinical study titled ‘An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy.’ The study aims to evaluate the long-term safety and efficacy of the drug Sevasemten (EDG-5506) in treating Becker muscular dystrophy, a condition that affects muscle function.
The study involves the administration of Sevasemten, an oral drug taken once daily, which is designed to improve muscle function and safety markers in patients with Becker muscular dystrophy.
This Phase 2 interventional study follows a single-group assignment model without masking, focusing primarily on treatment outcomes. The study is currently enrolling participants by invitation.
Key dates for this study include its initial submission on September 27, 2023, and the last update on September 2, 2025. These dates are crucial for tracking the study’s progress and any emerging results.
The update could positively influence the stock performance of Edgewise Therapeutics, Inc., as successful outcomes may boost investor confidence and position the company favorably against competitors in the muscular dystrophy treatment market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.